Nature Communications (Sep 2023)
Acquired miR-142 deficit in leukemic stem cells suffices to drive chronic myeloid leukemia into blast crisis
- Bin Zhang,
- Dandan Zhao,
- Fang Chen,
- David Frankhouser,
- Huafeng Wang,
- Khyatiben V. Pathak,
- Lei Dong,
- Anakaren Torres,
- Krystine Garcia-Mansfield,
- Yi Zhang,
- Dinh Hoa Hoang,
- Min-Hsuan Chen,
- Shu Tao,
- Hyejin Cho,
- Yong Liang,
- Danilo Perrotti,
- Sergio Branciamore,
- Russell Rockne,
- Xiwei Wu,
- Lucy Ghoda,
- Ling Li,
- Jie Jin,
- Jianjun Chen,
- Jianhua Yu,
- Michael A. Caligiuri,
- Ya-Huei Kuo,
- Mark Boldin,
- Rui Su,
- Piotr Swiderski,
- Marcin Kortylewski,
- Patrick Pirrotte,
- Le Xuan Truong Nguyen,
- Guido Marcucci
Affiliations
- Bin Zhang
- Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute
- Dandan Zhao
- Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute
- Fang Chen
- Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute
- David Frankhouser
- Department of Computational and Quantitative Medicine, City of Hope Medical Center and Beckman Research Institute
- Huafeng Wang
- Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute
- Khyatiben V. Pathak
- Cancer & Cell Biology Division, Translational Genomics Research Institute
- Lei Dong
- Department of Systems Biology, Beckman Research Institute of City of Hope
- Anakaren Torres
- Cancer & Cell Biology Division, Translational Genomics Research Institute
- Krystine Garcia-Mansfield
- Cancer & Cell Biology Division, Translational Genomics Research Institute
- Yi Zhang
- Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute
- Dinh Hoa Hoang
- Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute
- Min-Hsuan Chen
- City of Hope National Medical Center, Integrative Genomics Core, Department of Computational and Quantitative Medicine, Beckman Research Institute
- Shu Tao
- City of Hope National Medical Center, Integrative Genomics Core, Department of Computational and Quantitative Medicine, Beckman Research Institute
- Hyejin Cho
- City of Hope National Medical Center, Integrative Genomics Core, Department of Computational and Quantitative Medicine, Beckman Research Institute
- Yong Liang
- DNA/RNA Peptide Shared Resources, Beckman Research Institute
- Danilo Perrotti
- Department of Medicine and Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine Baltimore
- Sergio Branciamore
- Department of Computational and Quantitative Medicine, City of Hope Medical Center and Beckman Research Institute
- Russell Rockne
- Department of Computational and Quantitative Medicine, City of Hope Medical Center and Beckman Research Institute
- Xiwei Wu
- City of Hope National Medical Center, Integrative Genomics Core, Department of Computational and Quantitative Medicine, Beckman Research Institute
- Lucy Ghoda
- Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute
- Ling Li
- Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute
- Jie Jin
- Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University
- Jianjun Chen
- Department of Systems Biology, Beckman Research Institute of City of Hope
- Jianhua Yu
- Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Michael A. Caligiuri
- Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center
- Ya-Huei Kuo
- Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute
- Mark Boldin
- Department of Systems Biology, Beckman Research Institute of City of Hope
- Rui Su
- Department of Systems Biology, Beckman Research Institute of City of Hope
- Piotr Swiderski
- DNA/RNA Peptide Shared Resources, Beckman Research Institute
- Marcin Kortylewski
- Department of Immuno-Oncology, Beckman Research Institute
- Patrick Pirrotte
- Cancer & Cell Biology Division, Translational Genomics Research Institute
- Le Xuan Truong Nguyen
- Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute
- Guido Marcucci
- Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute
- DOI
- https://doi.org/10.1038/s41467-023-41167-z
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 21
Abstract
Abstract The mechanisms underlying the transformation of chronic myeloid leukemia (CML) from chronic phase (CP) to blast crisis (BC) are not fully elucidated. Here, we show lower levels of miR-142 in CD34+CD38− blasts from BC CML patients than in those from CP CML patients, suggesting that miR-142 deficit is implicated in BC evolution. Thus, we create miR-142 knockout CML (i.e., miR-142 −/− BCR-ABL) mice, which develop BC and die sooner than miR-142 wt CML (i.e., miR-142 +/+ BCR-ABL) mice, which instead remain in CP CML. Leukemic stem cells (LSCs) from miR-142 −/− BCR-ABL mice recapitulate the BC phenotype in congenic recipients, supporting LSC transformation by miR-142 deficit. State-transition and mutual information analyses of “bulk” and single cell RNA-seq data, metabolomic profiling and functional metabolic assays identify enhanced fatty acid β-oxidation, oxidative phosphorylation and mitochondrial fusion in LSCs as key steps in miR-142-driven BC evolution. A synthetic CpG-miR-142 mimic oligodeoxynucleotide rescues the BC phenotype in miR-142 −/− BCR-ABL mice and patient-derived xenografts.